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superior to image guidance every other fraction concerning 
adequate target coverage with minimal margins.
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Bildgesteuerte intensitätsmodulierte Strahlentherapie 
des Prostatakarzinoms
Analyse interfraktioneller Abweichungen und 
Akutreaktionen
Zusammenfassung
Ziel Ziel der Studie war es, die interfraktionelle Variabilität 
der Patientenlagerung und Prostataposition, den Einfluss der 
Bildgebungsfrequenz und die akuten Strahlenreaktionen bei 
einer hochdosierten bildgesteuerten intensitätsmodulierten 
Strahlentherapie (IG-IMRT) des Prostatakarzinoms zu 
untersuchen.
Methoden IG-IMRT wurde durch tägliche Verifikation von 
implantierten röntgendichten Prostatamarkern mittels Mega-
volt-Bildgebung (“electronic portal imaging device”, EPID) 
und anschließender Patientenrepositionierung vor Strahlen-
therapie erreicht. Insgesamt 1011 bildgesteuerte Fraktionen 
von 23 nacheinander behandelten, unselektierten Patienten 
wurden analysiert. Die mediane Gesamtbehandlungsdosis 
betrug 79,2 Gy (Spanne 77,4–81,0 Gy). Akutreaktionen 
wurden wöchentlich mittels der Common Terminology 
Criteria for Adverse Events (CTCAE) v.4.03 erfasst.
Ergebnisse Der Zufallsfehler der Gesamtpopulation 
durch die Variabilität der Patientenlagerung und Prostata-
position betrug 4–5 mm. Bildgesteuerte Strahlentherapie 
(IGRT) würde bei jeder zweiten Bestrahlungsfraktion 
Abstract
Purpose The aim of the study was to estimate interfraction-
al deviations in patient and prostate position, the impact of 
the frequency of online verification on the treatment mar-
gins, and to assess acute radiation reactions of high-dose ex-
ternal beam image-guided intensity-modulated radiotherapy 
(IG-IMRT) of localized prostate cancer.
Patients and methods IG-IMRT was performed by daily 
online verification of implanted fiducial prostate mark-
ers using a megavoltage electronic portal imaging device 
(EPID). A total of 1011 image-guided treatment fractions 
from 23 consecutive unselected prostate cancer patients 
were analyzed. The median total dose was 79.2 Gy (range 
77.4–81.0 Gy). Acute radiation reactions were assessed 
weekly during radiotherapy using the Common Terminol-
ogy Criteria for Adverse Events (CTCAE) v.4.03.
Results A relevant combined patient set-up and prostate 
motion population random error of 4–5 mm was observed. 
Compared to daily IGRT, image guidance every other day 
required an expansion of the CTV–PTV (clinical target 
volume–planning target volume) margin of 8.1, 6.6, and 
4.1 mm in the longitudinal, vertical, and lateral directions, 
thereby, increasing the PTV by approximately 30–40 %. No 
grade 3 or 4 acute radiation reactions were observed with 
daily IG-IMRT.
Conclusion A high dose with surprisingly low acute tox-
icity can be applied with daily IG-IMRT using implanted 
fiducial prostate markers. Daily image guidance is clearly 
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im Vergleich zu täglicher IGRT eine Erweiterung des 
CTV(klinisches Zielvolumen)-PTV(Planungszielvolumen)-
Sicherheitssaums von 8,1 mm, 6,6 mm und 4,1 mm in der 
longitudinalen, vertikalen und lateralen Ebene erfordern. 
Dies würde eine Vergrößerung des PTV von etwa 30–40 % 
bedeuten. Bei der IG-IMRT mit täglicher Bildgebung 
wurden in der vorliegenden Studie keine Grad-3- oder 
Grad-4-Akutreaktionen beobachtet.
Schlussfolgerung Bei einer IG-IMRT mit täglicher Veri-
fikation von Prostatamarkern kann eine hohe Dosis mit 
überraschend geringer Akuttoxizität appliziert werden. Im 
Hinblick auf adäquate Tumorerfassung mit geringstmög-
lichen Sicherheitssäumen ist die tägliche IGRT einer IGRT 
bei jeder zweiten Bestrahlungsfraktion deutlich überlegen.
Schlüsselwörter Prostataneoplasien · Bildgesteuerte 
Strahlentherapie · Intensitätsmodulierte Strahlentherapie · 
Planungszielvolumen · Röntgendichte Marker
Several meta-analyses have shown that higher doses of 
radiotherapy improve the biochemical relapse-free survival 
of patients with organ-confined prostate cancer compared to 
those treated with conventional-dose radiotherapy [7, 22]. 
Higher radiation doses potentially increase the risk of acute 
and late radiation toxicity. In order to keep the risk of acute 
and late radiation toxicity as low as possible, the radiothera-
peutic high-dose region should be as small as possible.
Early studies revealed a relevant prostate motion vari-
ability [20], evaluated the patient set-up variability without 
image guidance [15], and estimated the treatment margins 
for the combined error of both factors [17]. Image-guided 
radiotherapy (IGRT) and reverse planned intensity-modu-
lated radiotherapy (IMRT) are current radiation techniques 
commonly used to minimize the high-dose region without 
compromising tumor coverage for the definitive radiother-
apy of localized prostate cancer. IGRT reduces the high-
dose volume by minimizing the required internal margin 
(IM) and set-up margin (SM), thereby, downsizing the plan-
ning target volume (PTV). IMRT reduces the high-dose vol-
ume by generating a dose distribution more conformal to the 
PTV compared to conventional three-dimensional confor-
mal radiotherapy (3DCRT).
In this study, IGRT was achieved with daily online verifi-
cation of implanted fiducial prostate markers using an elec-
tronic portal imaging device (EPID). The goal of the study 
was to assess prostate motion variability and patient set-up 
variability, and to estimate the safety margin to accommo-
date for the combined error of both factors. Furthermore, the 
impact of the frequency of the image guidance (every fraction 
versus every other fraction versus no image guidance) on the 
CTV–PTV margin was estimated. Acute radiation reactions 
were assessed weekly during radiotherapy to evaluate the tol-
erance to high radiation doses applied using daily IG-IMRT.
Patients and methods
Patient data and preparation for treatment planning
A total of 23 consecutive, unselected patients receiving 
definitive radiotherapy for localized prostate cancer between 
December 2013 and March 2015 were analyzed. The his-
topathological diagnosis was established by transrectal 
ultrasonography (TRUS)-guided biopsy. Usually 12 cores 
were taken per prostate. Prior to radiotherapy, all patients 
underwent implantation of three prostate gold markers 
(1.2 × 3.0 mm in size; Civco Medical Solutions, Coralville, 
IA, USA) into the prostate under TRUS guidance to enable 
image-guided radiotherapy. The three prostate gold mark-
ers were placed in the prostate base, mid-gland, and apex. 
After an interval of 3 days, the patients underwent a com-
puted tomography (CT) scan and magnetic resonance imag-
ing (MRI) in the supine position for radiotherapy planning. 
The CT simulation was performed without contrast medium 
using a 64-slice spiral CT scanner (Somatom Sensation 64, 
Siemens Healthcare, Erlangen, Germany) with a slice thick-
ness of 3 mm. The MRI was performed using a 3 T MRI 
scanner (Magnetron Trio, Siemens Healthcare, Erlangen, 
Germany). The slice thickness was 2 mm. Five sequences 
(axial T1w, axial T2w, coronal T2 STIR, axial T1FS) were 
obtained before and three sequences (axial, sagittal, and cor-
onal T1FS) after the application of contrast media. The MRI 
and CT images were electronically fused using the Auto-
Register method of the syngo®-based Coherence Oncologist 
Workspace version 2.0.52 (Siemens Healthcare, Erlangen, 
Germany). The Auto-Register method uses a “(Normalized) 
Mutual Information” algorithm which is based on infor-
mation theory (entropy). The target volumes were defined 
using the fused images. MRI images were used for the tar-
get volume definition in particular because the apex of the 
prostate can be better visualized using MRI compared to CT 
[13, 23]. For CT simulation and radiotherapy, patients were 
immobilized in supine position using a headrest, kneefix, 
and feetfix (Civco Medical Solutions, Coralville, IA, USA). 
The CT simulator and the linear accelerators were equipped 
with identical models of a carbon index tables and position-
ing devices. Patients were instructed to have a comfortably 
filled bladder and an empty rectum for their CT and MRI 
examinations and for each treatment appointment.
The study was approved by the local institutional ethical 
committee and conducted in accordance with the Helsinki 
Declaration in its current version.
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The patient set-up error was represented by the deviation 
of the compared bony landmarks. The prostate motion error 
was represented by the deviation of the compared fiducial 
prostate markers after matching of the bony landmarks. The 
combined error of both factors (referred to as “combined 
error”) was represented by the deviation of the compared 
fiducial prostate markers. Online correction of deviation of 
the fiducial prostate markers was done by automatic adjust-
ment of the treatment table in three dimensions prior to 
every radiotherapy application in all patients.
Inverse-planned intensity-modulated radiotherapy
The target volumes were defined and the dose prescribed 
according to the International Commission on Radiation 
Units and Measurement (ICRU) Reports 50 and 62 recom-
mendations. Accordingly, the PTV should be surrounded by 
the 95 % isodose line. The contouring of the PTV and organs 
at risk was done according to the RTOG Consensus Con-
touring Guidelines “Male Pelvis Normal Tissue” and other 
specific recommendations [13, 23]. In very low risk and low 
risk patients the CTV included the prostate gland. In one 
Image-guided radiotherapy
At the first radiotherapy fraction, megavoltage electronic 
portal images were taken using an electronic portal imag-
ing device (EPID, [16]) from orthogonal directions (0° 
or 180° and 270° or 90°) and from the directions of the 
treatment beams. At all following radiotherapy fractions 
megavoltage electronic portal images were taken from two 
orthogonal directions. Processing and analysis software 
was used to significantly improve the image quality of the 
megavoltage electronic portal images [10]. Representa-
tive pelvic bony landmarks and the three fiducial prostate 
markers were marked on the portal images using electronic 
drawing tools. The images were zoomed and electronically 
superposed with the reference images, the corresponding 
digitally reconstructed radiographs (DRR) generated by the 
treatment planning system (TPS). A portal imaging software 
was used to assess the isocenter placement error in three 
dimensions based on the comparison of bony landmarks or 
fiducial prostate markers of the portal images with the cor-
responding reference image (Fig. 1).
Fig. 1 Online verification of bony 
landmarks and implanted fiducial 
prostate markers using megavolt-
age X-rays and electronic portal 
imaging device (EPID). a Digital 
reconstructed radiograph (DRR) 
generated by the treatment plan-
ning system. The position of the 
three fiducial prostate markers 
is marked with crosses. b Portal 
image (double-exposed) obtained 
immediately before the radiother-
apy fraction using the EPID. The 
three dots represent the fiducial 
prostate markers. c Fused images 
of a and b. d Calculated devia-
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image guidance every other radiotherapy fraction or no image 
guidance during radiotherapy, the patient set-up and prostate 
motion error before correction of the corresponding radiother-
apy fractions was used for the statistical analysis. Treatment 
margins were calculated using the van Herk formula [21]. 
Accordingly, the margin required to ensure 95 % minimum 
dose to the PTV for 90 % of the patients was given by
M
ptv p
= + −∑2 50 1 64 1 64. . .σ σ
 
where S is the square root of the quadratic sum of the stan-
dard deviations of all contributing systematic errors, s the 
square root of the quadratic sum of the standard deviations 
of all contributing random errors, and σ
p
 the standard devi-
ation describing the width of the penumbra. In our analysis 
Sset-up was used as contributing systematic error, and σset up−  
and σ
p
 as contributing random errors ( )σ σ σ= +−set up p
2 22 . 
The representative standard deviation of the penumbra width 
σ
p
 of our linear accelerators was 4.2 mm.
Results
A total of 1011 image-guided treatment fractions from 
23 subsequent unselected prostate cancer patients were 
obtained for analysis. The number of radiotherapy fractions 
per patient ranged from 43 to 45. Patient and treatment char-
acteristics are listed in Table 1. The patient set-up variability, 
prostate motion variability, and the combined error of both 
factors (referred to as combined error) were slightly differ-
ent in the three dimensions. On average, the patient set-up 
variability was greater than the prostate motion variability. 
Most probably due to differences in the bladder and rectum 
filling [20, 21] and respiration [4] the prostate motion vari-
ability was greater in the longitudinal and vertical direction 
than in the lateral direction. All errors were compatible with 
a Gaussian distribution (Fig. 2). The mean combined error 
appeared to be constant during the course of the radiother-
apy (Fig. 3). Image guidance every other fraction compared 
to no image guidance substantially reduced the combined 
error. However, considerable error remains after image 
guidance every other fraction. The mean combined error 
varied considerably between and within the patients, and 
depending on the direction deviations greater than 3, 5, and 
10 mm were found on average in 22–29 %, 10–21 %, and 
4–10 % of the radiotherapy fractions after image guidance 
every other fraction (Fig. 4). The patient set-up variability, 
prostate motion variability, and the required safety margin 
to accommodate for the combined error in dependence of 
the frequency of the image guidance are listed in Table 2. 
Intrafractional errors were not investigated in this study.
(1)
patient with very high risk, the CTV included the prostate, 
the complete seminal vesicals, and the locoregional pelvic 
lymph nodes. In all other patients the prostate gland and the 
proximal seminal vesicals were included in the CTV. The 
CTV to PTV margin for the prostate gland was 5 mm and for 
the seminal vesicals 8 mm. The IMRT plans were generated 
using the TPS XIO 4.4 (CMS, Inc., St. Louis, MO, U.S.A.). 
The normal tissue dose volume constraints provided by the 
TPS were used for the IMRT plans. Tissue inhomogeneities 
were considered in the treatment planning optimization pro-
cess, and the dose calculation algorithm used was “super-
position”. An optimization with 100 iterations was applied, 
followed by a semiautomatic segmentation (minimum 
3 cm step size). Segments with less than or equal 2 MU 
were expelled from the plan. A step-and-shoot technique 
was used with usually eight equally spaced coplanar fields. 
The number of segments of a typical plan was around 100 
and the corresponding treatment time about 15 min. Linear 
accelerators (Oncor Avant Garde, Siemens Medical, Erlan-
gen, Germany) equipped with a multileaf collimator (160 
leaves) and an EPID (Optivue, Siemens Medical, Erlangen 
Germany) were used for the treatment.
Assessment of acute radiation reactions
Acute radiation reactions were prospectively assessed by 
two Radiation Oncologists using the Common Terminol-
ogy Criteria for Adverse Events (CTCAE) v.4.03. The acute 
reactions were assessed once weekly during the course of 
radiotherapy and 6 weeks after radiotherapy.
Statistical analysis
Individual and population based parameters of the patient 
set-up variability were calculated according to the report “On 
target: ensuring geometric accuracy in radiotherapy” by The 
Royal College of Radiologists [14]. Accordingly, the individ-
ual mean patient set-up error Mindividual was defined as the mean 
set-up error for an individual patient. The overall population 
mean set-up error Mpop was defined as the overall mean for 
the analyzed patient group. The population systematic error 
Sset-up was defined as the standard deviation of the individual 
mean set-up error about the overall mean Mpop. The individual 
random (daily) positioning error sindividual was defined as the 
standard deviation of the set-up error around the correspond-
ing mean individual value Mindividual. The population random 
error sset-up was defined as the mean of all individual random 
errors sindividual. The patient set-up parameters were calculated 
for each direction (longitudinal, vertical, and lateral).
Image-guided correction of the patient set-up and prostate 
motion error was performed prior to every radiotherapy frac-
tion in all patients. In order to estimate the margins required for 
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cated”). Grade 3 or 4 has not been defined. In contrast, the 
Acute Radiation Morbidity Scoring Criteria of the Radiation 
Therapy Oncology Group (RTOG) categorizes genitouri-
nary morbidity into grades 0–4. This should be considered 
if results are compared. However, only 2 patients (13 %) of 
our study population developed CTCAE v. 4.03 grade 2 uri-
nary frequency (Table 3).
Discussion
In our study, IGRT was achieved by daily online verifica-
tion of implanted fiducial prostate markers. In order to save 
cost in terms of increased dose and in-room time [9], the 
question arises whether the frequency of image guidance 
can be reduced from daily to every other day without losing 
relevant benefit.
Our data show that the combined patient set-up and pros-
tate motion error on average remains basically constant over 
the course of radiotherapy. A small number of image-guided 
treatment fractions at the beginning of the radiotherapy 
course should therefore be sufficient to significantly reduce 
the systematic error. However, our data also reveal a popula-
tion random error of 4–5 mm in all directions, and that the 
random error varied grossly between and within the patients. 
For this reason, CTV–PTV margins derived from popula-
tion-based observations would lead to unnecessarily large 
PTVs in many patients. The impact of the random error on 
the CTV–PTV margin can be significantly reduced by daily 
online verification of the prostate position with necessary 
corrections applied before delivery of treatment. Our data 
show that with this approach in combination with the use 
of IMRT high doses of 77.4–81.0 Gy can be delivered with 
surprisingly low acute radiation toxicity. According to the 
van Herk formula, reducing the frequency of image-guided 
fractions to every other fraction would require an expansion 
of the CTV–PTV margin of 4–8 mm. This additional mar-
gin would increase the PTV by approximately 30–40 % in 
a typical prostate cancer patient. It is likely that an increase 
of the PTV of this magnitude will significantly increase the 
risk of toxicity at the high radiation doses prescribed.
Similar results have been reported by Kupelian et al. [11]. 
In their study, prostate cancer patients were treated with 
helical tomotherapy and megavoltage computed tomogra-
phy images were used for image guidance with intrapros-
tatic metallic fiducials. In agreement with our study, imaged 
guidance every other day compared to daily image guidance 
would have increased the CTV–PTV margin by 4–7 mm 
using the van Herk formula. The authors concluded that 
high-dose external beam radiotherapy for localized prostate 
cancer delivered with tight treatment margins requires daily 
image guidance.
In two patients a migration of one of the three fiducial 
prostate markers was detected. In one patient a fiducial 
prostate marker migration was observed between the CT 
simulation and the first radiotherapy fraction. In another 
patient a migration of a fiducial prostate marker of 4 mm 
was observed at radiotherapy fraction number 37. A loss of 
a fiducial prostate marker was not observed.
Acute radiation reactions were assessed weekly through-
out the course of radiotherapy and 6 weeks after radiother-
apy using CTCAE v.4.03. Despite the high radiation dose of 
77.4–81.0 Gy applied no grade 3 or 4 acute radiation reac-
tions were observed. Grade 2 acute reactions were detected 
in 4.3–56.5 %, and grade 1 in 13.0–78.3 % of the patients 
(Table 3). It should be noted that the common acute reac-
tion “urinary frequency” is categorized in CTCAE v. 4.03 as 
grade 0, grade 1 (“present”), and grade 2 (“limiting instru-
mental activities of daily living; medical management indi-




















Risk group (NCCN guidelines)a










4–6 months 6 26.1
2–3 years 13 56.5
LN Locoregional lymph nodes, ADT androgen deprivation therapy.
aGuidelines of the National Comprehensive Cancer Network.
bDose per fraction was 1.8 Gy in all patients.
cADT was given during radiotherapy.
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grade 2 and higher GI toxicity with IMRT. Guckenberger 
et al. [6] analyzed 150 prostate cancer patients treated with 
dose-escalated, moderately hypofractionated cone-beam CT 
based IG-IMRT with a simultaneous integrated boost (SIB) 
technique. Acute genitourinary (GU) toxicity grade 1–2 was 
observed in 85 % of the patients. Gastrointestinal (GI) toxic-
ity was mild with more than 80 % of the patients free from 
any GI toxicity during follow-up. Two patients suffered 
from late grade 3 GI toxicity. The rate of GU toxicity grade 
2 or higher was less than 10 % at 6–12 months but increased 
continuously to 22.4 % at 60 months; grade 3 GU toxicity 
remained below 5 % during follow-up. Crehange et al. [3] 
evaluated the impact of PTV reduction when delivering IG-
IMRT for patients with prostate cancer. The median dose 
prescribed to the prostate was 78 Gy (range 74–78 Gy). The 
incidence of grade 2 late genitourinary toxicity was 7.0 % 
for patients with a CTV–PTV margin of 5 mm (n = 87) 
and 6.6 % for patients with a CTV–PTV margin of 10 mm 
(n = 78; p = 1.00). The incidence of grade 2 late gastrointesti-
nal toxicity was 1.2 and 2.6 % (p = 0.38), respectively.
The limitations of tracking the prostate position using 
implanted fiducial prostate markers should be mentioned. 
Changes of the prostate shape, rotational changes of the 
prostate position [5, 24] as well as intrafractional errors 
Clinical data concerning toxicity of IG-IMRT in daily 
practice are scarce. Takeda et al. [19] reported about 141 
patients with localized prostate cancer treated with IG-
IMRT to a total dose of 76 Gy (n = 13) and 80 Gy (n = 128). 
No grade 3 or 4 acute toxicities were observed. The inci-
dence of grade 2 acute gastrointestinal (GI) and genitouri-
nary (GU) toxicities were 1.4 and 8.5 %, respectively. The 
5-year actuarial likelihood of grade 2–3 GI and GU late tox-
icities were 6 and 6.3 %, respectively. There was no grade 4 
GI or GU late toxicity. Wortel et al. [25] assessed the acute 
radiation toxicity of patients treated to 78 Gy with either IG-
IMRT (n = 260) or 3D-CRT (n = 215) using toxicity ques-
tionnaires distributed at baseline, prior to fraction 20 and 30, 
and at 90 days after treatment. IG-IMRT resulted in signifi-
cantly lower overall RTOG grade 2 or higher GI toxicity (29 
versus 49 %, respectively, p = 0.002) and overall GU grade 2 
and higher toxicity (38 versus 48 %, respectively, p = 0.009). 
Michalski et al. [12] compared 491 patients treated with 
3D-CRT and 257 with IMRT to a total dose of 79.2 Gy. 
For grade 2 and higher acute gastrointestinal/genitourinary 
(GI/GU) toxicity, both univariate and multivariate analyses 
showed a statistically significant decrease in grade 2 and 
higher acute collective GI/GU toxicity for IMRT. There 
was a trend for a clinically meaningful reduction in late 
Fig. 2 Patient set-up variability, prostate motion variability, and the combined error of both factors. The red lines represent the corresponding 
Gaussian distribution
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Fig. 3 Combined error of the 
patient set-up variability and 
prostate motion variability during 
the course of radiotherapy. The 
squares represent the mean and 
the vertical lines the range of the 
deviation
Fig. 4 Frequency of the combined error of patient set-up variability and prostate motion variability larger than threshold. The filled symbols rep-
resent the population mean, the box the standard error, and the horizontal lines the mean of individual patients
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distribution can be achieved by daily CT-based image guid-
ance [1, 8] in combination with gating or tracking of the tar-
get, thereby, considering inter- and intrafractional changes 
[2].
Conclusion
A high dose with surprisingly low acute toxicity can be 
applied with daily IG-IMRT using implanted fiducial pros-
tate markers for the definitive external beam radiotherapy of 
localized prostate cancer. Daily image guidance is clearly 
superior compared to image guidance every other fraction 
concerning adequate target coverage with minimal margins.
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